Expression of TTF-1, NapsinA, P63, CK5/6 in Lung Cancer and Its Diagnostic Values for Histological Classification

YU He, LI Lei, LIU Dan. et al

Abstract

To investigate the expressions of thyroid transcription factor-1(TTF-1), NapsinA, P63 and CK5/6 in lung cancer tissues and their diagnostic value for histological classification. Methods The protein expression in a total of 964 lung cancer samples was detected by immunohistochemistry, of which 929 cases for TTF-1, 113 cases for NapsinA, 282 cases for P63, and 277 for CK5/6, respectively. The correlations between the protein expressions of the four markers and clinicopathological features in lung cancer patients were analyzed. The area under the curves (AUCs) of ROC curves, sensitivity and specificity were calculated to determine the diagnostic values for the four markers. Results There were 552 cases of lung adenocarcinoma (ADC), 146 cases of lung squamous cell carcinoma (SCC), 253 cases of small cell carcinoma (SCLC), and 13 cases of large cell carcinoma (LCC). The median age was 56 years old, and 63.4% was male. The positive expression rates of TTF-1, NapsinA, P63, and CK5/6 were 76.3% (709/929), 67.3% (76/113) , 47.2% (133/282) and 34.7% (96/277), respectively. The positive expression rates of TTF-1 and NapsinA were higher in lung ADC, and the sensitivity and specificity of TTF-1 in the diagnosis of ADC were 81.15% and 30.41% respectively, those of NapsinA were 82.05% and 65.71% respectively. The AUCs for TTF-1 and NapsinA were 0.557 8 (P=0.002 6,95%CI：0.520 0-0.595 6) and 0.738 8 (PCI:0.633 4-0.844 2) respectively. The positive expression rates of P63 and CK5/6 were significantly higher in lung SCC, and their sensitivities to diagnose SCC were 80.68% and

 

Keywords: TTF-1, NapsinA, P63 CK5/6, Lung cancer, Histological classification 

 

Full Text:

PDF


References


TORRE L A, BRAY F, SIEGEL RL.et al. Global cancer statistics, 2012. CA Cancer J Clin,2015,65(2) ;87-108.

ETTINGER DS, WOOD DE. AKERLEY W, et al. NCCN guidelines insights; non-small cell lung cancer, version 4. 2016. J Natl Compr Cane Netw,2016,14(3): 255-264.

TRAVIS WD, BRAMBILLA E, NICHOLSON AG, et al. The 2015 World Health Organization classification of lung tumors; impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol, 2015, 10 ( 9): 1243-1260.

LOO PS, THOMAS SC, NICOLSON MC.ei at. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol.2010,5(4) ;442-447.

NICHOLSON AG, GONZALEZ D, SHAH P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol, 2010, 5 ( 4 ) ; 436- 441.

NONAKA D. A study of deltaNp63 expression in lung non-small cell carcinomas. Am J Surg Pathol, 2012, 36 ( 6); 895- 899.

ORDONEZ NG. Value of thyroid transcription factor-1 immunostaining in tumor diagnosis; a review and update. Appl Immunohistochem Mol Morphol,2012,20(5) :429-444. EDGE SB,COMPTON CC. The american joint committee on cancer; the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol,2010,17(6): 1471- 1474.

SUN JM, HAN J, AHN JS, el at. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol. 2011.6(8): 1392-1399.

ZHANG P, HAN YP, HUANG U et al. Value of napsin A and thyroid transcription factor-1 in the identification of primary lung adenocarcinoma. Oncol Lett. 2010. 1 (5): 899-

PERNER S, WAGNER PL. SOLTERMANN A,et al. TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol, 2009,217(1);65-72.

LAZZARO D, PRICE M. DE FELICE M, et al. The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain. Development, 1991 ,113(4): 1093-1104.

CHUMAN Y, BERGMAN A, UENO T,et al. Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas. FEBS Lett, 1999,462( 1/2) ; 129-134.

KIMMJ, SHIN HC, SHIN КС, et al. Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens. Ann Diagn Pathol, 2013,17(1) :85-90.

WHITHAUS K. FUKUOKA J, PRIHODA TJ, et al. Evaluation of napsin A, cytokeratin 5/6, p63. and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung. Arch Pathol Lab Med,2012,136(2): 155-162.

REKHTMAN N, ANG DC, SIMA CS, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol,2011,24(10) s 1348-1359.

MUKHOPADHYAY S, KATZENSTEIN AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol,2011 ,35( 1); 15-25.

ZHANG C, SCHMIDT LA, HATANAKA K, et al. Evaluation of napsin A, TTF-1, p63, plO, and CK5/6 immunohistochemical stains in pulmonary neuroendocrine tumors. Am J Clin Pathol.2014,142(3) :320-324.

XU XY, YANG GY, YANG JH,et al. Analysis of clinical characteristics and differential diagnosis of the lung biopsy specimens in 99 adenocarcinoma cases and 111 squamous cell carcinoma cases; utility of an immunohistochemical panel containing CK5/6, CK34betaE12, рбЗ, CK7 and TTF-1. Pathol Res Pract,2014 ,210( 10) :680-685.

YANG A, SCHWEITZER R. SUN D.et al. P63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature, 1999,398(6729);714-718. MILLS AA, ZHENG B, WANG XJ, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature, 1999,398(6729):708-713.

KOSTER MI, KIM S, MILLS AA, et al. P63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev, 2004 ,18(2); 126-131.

SENOO M, PINTO F, CRUM С P.et al. p63 is essential for the proliferative potential of stem cells in stratified epithelia. Cell,2007,129(3) ;523-536.


Refbacks

  • There are currently no refbacks.